TCT 2022: Sentinel® Cerebral Stroke Protection System During Transcatheter Aortic Valve Replacement

Подробнее о видео

Watch on Radcliffe Cardiology: *la7hgg*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2MzY3NjM5Ny4zMTUuMS4xNjYzNjc4OTUyLjAuMC4w

In this short interview, Dr Samir Kapadia (Cleveland Clinic, OH, US) outlines the findings of the PROTECTED-TAVR trial, which aimed to demonstrate the performance of Boston Scientific's Sentinel® Cerebral Protection System in transcatheter aortic valve replacement.

In this study, 3000 patients were randomized to receive either TAVR with the Sentinel system or TAVR without intervention. The participants' outcomes were then compared to evaluate the risk of peri-procedural stroke (≤72 hours) after the procedure.

Questions:
1. What is the importance of this trial?
2. Can you briefly tell us about the Sentinel® Cerebral Protection System?
3. What is the study design, patient selection criteria and endpoints?
4. What are the key results?
5. What were the challenges with running this trial?
6. How should this impact practice and future research?

Recorded remotely from Cleveland, 2022.
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.